Subscribe To
Humacyte to announce top line data from phase 2/3 v005 trial in vascular trauma evaluating its human acellular vessel™ (hav™) tuesday, september 12, 2023 at 8:00 am et
Virtual Webinar to Include Key Opinion Leader Perspectives on the Potential of the HAV in Vascular Trauma Repair DURHAM, N.C., Sept. 11, 2023 (GLOBE N...
September 11, 2023, 9:00 pm
Mcdonald's to scrap self-serve soda fountains over theft, hygiene concerns: report
The fast food restaurant chain plans to phase out the do-it-yourself feature -- eliminating the soda fo...
September 11, 2023, 3:45 pm
Why shares of eyepoint pharmaceuticals were rising monday
EyePoint reported top-line data on two phase 2 trials for its lead pipeline candidate. The company focu...
September 11, 2023, 3:20 pm
Bristol myers' (bmy) pulmonary fibrosis drug positive in phase ii
Bristol Myers (BMY) posts encouraging data from a phase II study in progressive pulmonary fibrosis....
September 11, 2023, 1:32 pm
Buenaventura (bvn) gets environmental approval for yumpag
Buenaventura (BVN) gains environmental approval for its Yumpag project, bringing it closer to the production phase....
September 11, 2023, 12:46 pm
Gilead's (gild) trodelvy combo shows promise in nsclc study
Gilead's (GILD) breast cancer drug Trodelvy, in combination with Keytruda, shows positive data in a phase ...
September 11, 2023, 12:46 pm
Boeing (ba) wins contract for glide breaker phase 2 program
Boeing (BA) secures a $70.6 million contract involving the Glide Breaker phase 2 program....
September 11, 2023, 12:01 pm
Cingulate announces detailed trial results from phase 3 adult efficacy and safety trial of ctx-1301 (dexmethylphenidate) for adhd
CTx-1301 Demonstrated Clinically Meaningful Improvements in Permanent Product Measure of Performance (PERMP) and Clinical Global Impression Scale (CGI...
September 11, 2023, 10:00 am
Biovie presents alzheimer's study data on patient's baseline characteristics
BioVie Inc (NASDAQ:BIVI) has unveiled early data from its phase 3 study of its investigational drug NE3...
September 11, 2023, 8:42 am
Nervgen pharma to present at 2023 international spinal research trust network meeting
Vancouver, British Columbia--(Newsfile Corp. - September 11, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a...
September 11, 2023, 8:30 am
Why is crinetics pharmaceuticals (crnx) stock up 64% today?
Crinetics Pharmaceuticals (NASDAQ: CRNX ) stock is on the rise Monday after the company announced positive clinical trial results. According to a pre...
September 11, 2023, 8:04 am
Crinetics pharmaceuticals shares surge 65%, analysts raise price target after acromegaly treatment results
Shares of Crinetics Pharmaceuticals Inc. CRNX, -1.18% gained 65% premarket on Monday after the company announced positive results from a late-stage st...
September 11, 2023, 8:01 am
Rayzebio sets ipo terms, to be valued at up to $1 billion
RayzeBio Inc. RYZB, has set terms for its initial public offering, as the California-based radiopharmaceutical company with a tumor treatment in a
September 11, 2023, 7:03 am
Plus therapeutics receives $1.9 million advance payment from cprit and plans to present at the cprit innovations in cancer prevention and research conference
AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical compa...
September 11, 2023, 7:00 am
Eagle pharmaceuticals to present cal02 trial in progress at the 2023 asm/escmid joint conference on drug development to meet the challenge of antimicrobial resistance
-- CAL02 is a unique therapeutic agent that is designed to work differently from antibiotics, aiming to disarm an infectious pathogen's virulence fact...
September 11, 2023, 6:50 am
Usd/jpy indicating a big figure lower than friday after 'exit' comments from boj gov ueda
A Japanese media report over the weekend, I posted earlier here:Bank of Japan Governor Ueda says his focus is on a 'quiet exit' reducing monetary easi...
September 10, 2023, 8:28 pm
Bank of japan governor ueda says his focus is on a 'quiet exit' reducing monetary easing
Japan media, Yomiuri:The Bank of Japan has entered a phase of reducing monetary easing. In an interview...
September 10, 2023, 8:04 pm
Stoke therapeutics is unable to derisk its platform
Stoke Therapeutics (STOK) stock is down 40% after failing to meet expectations in a phase 1/2 epilepsy ...
September 10, 2023, 5:08 pm
Crinetics’ once-daily oral paltusotine achieved the primary and all secondary endpoints in the phase 3 pathfndr-1 study evaluating treatment of patients with acromegaly
83% of Participants on Paltusotine Maintained IGF-1 ≤1.0 xULN vs. 4% on placebo (p<0.0001) Mean IGF-1 Levels Were Maintained on Paltusotine vs. an I...
September 10, 2023, 2:00 pm
Cymabay: positive phase 3 data and competitive advantage established
Positive results achieved in phase 3 RESPONSE study, which used seladelpar for the treatment of patient...
September 10, 2023, 6:05 am